SCHEMBL6388684

SCHEMBL6388684

[CH2]NC(=O)Nc1cccc(OC)c1

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TP53 P04637 3/20 0.71
TSHR P16473 1/20 0.71
RAB9A P51151 9/20 0.66
NPC1 O15118 7/20 0.66
ALDH1A1 P00352 5/20 0.66
MITF O75030 1/20 0.66
MAPT P10636 5/20 0.62
SMN1; SMN2 Q16637 5/20 0.62
HTT P42858 3/20 0.62
KMT2A Q03164 3/20 0.62
MEN1 O00255 2/20 0.62
LMNA P02545 1/20 0.62
MAPK1 P28482 1/20 0.62
STAT1 P42224 1/20 0.62
RXFP1 Q9HBX9 1/20 0.62
POLB P06746 1/20 0.61
USP2 O75604 1/20 0.61
GAA P10253 1/20 0.61
ALOX15 P16050 1/20 0.61
HSD17B10 Q99714 1/20 0.61

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4893387 0.90 TP53 (0.87) TP53TSHRRAB9ANPC1ALDH1A1
SCHEMBL31040569 0.90 TP53 (0.87) TP53TSHRRAB9ANPC1ALDH1A1
SCHEMBL17084260 0.88 TP53 (0.84) TP53TSHRRAB9ANPC1ALDH1A1
SCHEMBL14442613 0.85 TP53 (0.84) TP53TSHRRAB9ANPC1ALDH1A1
SCHEMBL7610775 0.85 TP53 (0.73) TP53TSHRRAB9ANPC1ALDH1A1
SCHEMBL6388689 0.85 TP53 (0.73) TP53TSHRRAB9ANPC1ALDH1A1
SCHEMBL9036588 0.83 TP53 (0.71) TP53TSHRRAB9ANPC1ALDH1A1
SCHEMBL6474439 0.83 TP53 (0.66) TP53TSHRRAB9ANPC1ALDH1A1
SCHEMBL7412529 0.82 TP53 (0.69) TP53TSHRRAB9ANPC1ALDH1A1
SCHEMBL22103808 0.82 TP53 (0.74) TP53TSHRRAB9ANPC1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6844366-B2 Sulfonamide hydroxamates SYNTEX (U.S.A.) LLC (US) 2005-01-18 US claimed
US-6787559-B2 HYDROXYCARBONYL OR ALKYLOXYCARBONYL OR AMINOHYDROXYCARBONYL SUBSTITUTED SULFONAMIDE COMPOUNDS USEFUL AS PROCOLLAGEN C-PROTENASE INHIBITOR SYNTEX (U.S.A.) LLC. 2004-09-07 US claimed
EP-1149072-B1 SULFONAMIDE HYDROXAMATES HOFFMANN LA ROCHE (CH) 2004-06-30 EP claimed
US-20030216405-A1 Hydroxycarbonyl or alkyloxycarbonyl or aminohydroxycarbonyl substituted sulfonamide compounds useful as procollagen C-protenase inhibitor BILLLEDEAU ROLAND JOSEPH (US) 2003-11-20 US claimed
US-20030199520-A1 Sulfonamide hydroxamates BILLLEDEAU ROLAND JOSEPH (US) 2003-10-23 US claimed
US-6492394-B1 PROCOLLAGEN C-PROTEINASE INHIBITORS; TREATING FIBROTIC DISEASES SYNTEX (U.S.A.) LLC 2002-12-10 US claimed
EP-1149072-A1 SULFONAMIDE HYDROXAMATES F. HOFFMANN-LA ROCHE AG (CH) 2001-10-31 EP claimed
WO-2000037436-A1 SULFONAMIDE HYDROXAMATES F. HOFFMANN-LA ROCHE AG (CH) 2000-06-29 WO claimed
US-6844366-B2 Sulfonamide hydroxamates SYNTEX (U.S.A.) LLC (US) 2005-01-18 US disclosed
US-6787559-B2 HYDROXYCARBONYL OR ALKYLOXYCARBONYL OR AMINOHYDROXYCARBONYL SUBSTITUTED SULFONAMIDE COMPOUNDS USEFUL AS PROCOLLAGEN C-PROTENASE INHIBITOR SYNTEX (U.S.A.) LLC. 2004-09-07 US disclosed
EP-1149072-B1 SULFONAMIDE HYDROXAMATES HOFFMANN LA ROCHE (CH) 2004-06-30 EP disclosed
US-20030216405-A1 Hydroxycarbonyl or alkyloxycarbonyl or aminohydroxycarbonyl substituted sulfonamide compounds useful as procollagen C-protenase inhibitor BILLLEDEAU ROLAND JOSEPH (US) 2003-11-20 US disclosed
US-20030199520-A1 Sulfonamide hydroxamates BILLLEDEAU ROLAND JOSEPH (US) 2003-10-23 US disclosed
US-6492394-B1 PROCOLLAGEN C-PROTEINASE INHIBITORS; TREATING FIBROTIC DISEASES SYNTEX (U.S.A.) LLC 2002-12-10 US disclosed
EP-1149072-A1 SULFONAMIDE HYDROXAMATES F. HOFFMANN-LA ROCHE AG (CH) 2001-10-31 EP disclosed
WO-2000037436-A1 SULFONAMIDE HYDROXAMATES F. HOFFMANN-LA ROCHE AG (CH) 2000-06-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030216405-A1 Hydroxycarbonyl or alkyloxycarbonyl or aminohydroxycarbonyl substituted sulfonamide compounds useful as procollagen C-protenase inhibitor CTSE, PREP, HPN TP53 1164/4885TSHR 4549/4885RAB9A 3062/4885
US-20030199520-A1 Sulfonamide hydroxamates MMP3, TIMP3, MMP13 TP53 2261/4885TSHR 3046/4885RAB9A 4787/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.